Navigation Links
Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.

EXTON, Pa., April 4, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. (TMI) for an undisclosed upfront payment and future development milestones. TMI, a biotechnology company headquartered in King of Prussia, PA, developed the tumor-targeting peptide (TTP) platform capable of delivering conjugated radionucleotides, chemotoxins, nanoparticles and optical dyes to tumor cells via systemic administration. The TTP technology has been validated in multiple preclinical studies and clinical trials that have demonstrated tumor-specific delivery of conjugated TTP.  

"While we are enthusiastic about the current technologies being utilized throughout our Eisai Product Creation Systems (EPCS) network to support our near-term pipeline goals," said Mr. Hideki Hayashi, Chief Product Creation Officer of Eisai Co., Ltd., "Our strategy is to continue to pursue access to new cutting-edge technologies that will enable us to further support our current and future pipeline objectives as we strive to develop highly innovative medicines to address the needs of patients with serious illnesses. The acquisition of the TMI tumor targeting platform is yet another step in our evolution to become a leader in developing disease-specific compounds that can target disease cells and/or treat the underlying cause of a targeted disease."

TMI's TTP was originally isolated from scorpion venom. The peptide was identified and pursued experimentally based on its ability to specifically bind and suppress growth of activated epithelial cells. Subsequent studies have found the peptide and engineered variants can bind be internalized by malignant cells via the annexin A2 complex.

"The acquisition of these TMI assets by Morphotek is an excellent outcome for TMI's investors, who will directly receive proceeds and potential future milestone payments from this transaction.  We have great confidence in Morphotek's ability to develop innovative therapies created from TMI's broadly enabling platform technology, and we look forward to seeing these therapies benefit patients," added Curt LaBelle, Director of the Board of TMI."

The transaction provides Morphotek and Eisai exclusive ownership of TTP for therapeutic and diagnostic uses.  Morphotek intends to pursue the TTP platform through collaboration with other EPCS units to develop TTP conjugates for treating a variety of different cancers.

About Morphotek

Morphotek, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology.  The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications.  The company is currently focusing its platform on the development and manufacturing of therapeutic proteins for the treatment of cancer, inflammation and infectious disease.  For more information, please visit

About Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business.  Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit Media Inquiries

Investor InquiriesTerry Cushmore

Rod DauschMorphotek, Inc.

Morphotek, Inc.610-423-6197   Media Inquiries

Investor InquiriesLynn Kenney

Alex Scott Eisai Inc.

Eisai Inc.201-746-2294

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
2. Spectrum Dynamics Announces Shipment of Revolutionary D-SPECT™ Cardiac Imaging Systems Using Redlens New CZT Nuclear Imaging Modules
3. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
4. Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize
5. International Isotopes Inc. Announces 2010 Year End Financial Results
6. Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
7. PAREXEL Announces Date of Third Quarter Fiscal Year 2011 Earnings Release and Conference Call
8. Milestone Scientific Announces 2010 Year End Results
9. PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
10. Volcano Announces Its Presence at American College of Cardiology 2011 (ACC.11)
11. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa ... and Sepsis conditions present in similar ways and require time-critical intervention to avoid large ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):